

Dynamic evolution of COVID-19 on chest computed tomography: experience from Jiangsu province of China

Yuan-Cheng Wang¹, Huanyuan Luo², Songqiao Liu³, Shan Huang¹, Zhen Zhou⁴, Qian Yu¹,
Shijun Zhang¹, Zhen Zhao¹, Yizhou Yu⁵, Yi Yang³, Duolao Wang², Shenghong Ju^{1*}

Authors and affiliations:

1. Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
2. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, United Kingdom
3. Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
4. School of Electronics Engineering and Computer Science, Peking University
5. Department of Computer Science, The University of Hong Kong, Hong Kong

Correspondence to:

Shenghong Ju, MD, Professor of Medicine

Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing,
China

87 Ding Jia Qiao Road, Nanjing 210009, China

Phone: 86-13914717911

E-mail: jsh0836@hotmail.com

1 **Title**

2 **Dynamic evolution of COVID-19 on chest computed tomography: experience from Jiangsu**
3 **province of China**
4
5
6

7
8 **Abstract**
9

10 **Objectives**

11 To determine the patterns of chest computed tomography (CT) evolution according to disease
12 severity in a large coronavirus disease 2019 (COVID-19) cohort in Jiangsu province, China.
13
14
15

16 **Methods**

17 This retrospective cohort study was conducted from January 10, 2020 to February 18, 2020. All
18 patients diagnosed with COVID-19 in Jiangsu province were included, retrospectively.
19
20

21 Quantitative CT measurements of pulmonary opacities including volume, density and location
22 were extracted by deep learning algorithm. Dynamic evolution of these measurements was
23 investigated from symptom onset (day 1) to beyond day 15. Comparison was made between
24 severity groups.
25
26
27
28
29
30

31 **Results**

32 A total of 484 patients (median age of 47 years, interquartile range: 33-57) with 954 CT
33 examinations were included and each was assigned to one of three groups: asymptomatic/mild
34 (n=63), moderate (n=378), severe/critically ill (n=43). Time series showed different evolution
35 patterns of CT measurements in the groups. Following disease onset, posteroinferior subpleural
36 area of the lung was the most common location for pulmonary opacities. Opacity volume
37 continued to increase beyond 15 days in the severe/critically ill group, compared to peaking on
38 day 13-15 in the moderate group. Asymptomatic/mild group had the lowest opacity volume which
39 almost resolved after 15 days. The opacity density began to drop from day 10-12 for moderate ill
40 patients.
41
42
43
44
45
46
47
48
49
50

51 **Conclusions**

52 Volume, density and location of the pulmonary opacity and their evolution on CT varied with
53 disease severity in COVID-19. These findings are valuable in understanding the nature of the
54 disease and monitoring the patient's condition during the course of illness.
55
56
57
58

59 **Keywords:**
60
61
62

1. Coronavirus;
2. Multidetector computed tomography;
3. Viral pneumonia

Key points

- 1) Volume, density and location of the pulmonary opacity on CT change over time in COVID-19.
- 2) The evolution of CT appearance follows specific pattern, varying with disease severity.

Abbreviations:

AI = artificial intelligence

CI = confidence interval

COVID-19 = coronavirus disease 2019

CT = computed tomography

GGO = ground glass opacity

ICU = intensive care unit

IQR = interquartile range

SaO₂ = arterial oxygen saturation

SD = standard deviation

VOI = volume of interest

Introduction

At the end of 2019, an outbreak of a highly contagious viral pneumonia was reported in Wuhan, China and the causative agent was confirmed to be a novel coronavirus, termed as COVID-19 by World Health Organization [1]. The disease spread to all provinces in China and many countries overseas, leaving more than 400 thousand people infected as of March 25, 2020 [2][3]. Jiangsu province has the fifth largest population in China and has reported more than 600 infected cases [4].

Computed tomography (CT) examination plays an important role in the evaluation of COVID-19. According to the 5th edition of diagnosis and treatment standards for novel coronavirus pneumonia published by the Chinese National Health Commission, CT examination is one of the three main diagnostic criteria. In Hubei province the clinical diagnosis of COVID-19 comprises of only clinical and radiological proof, irrespective of the nucleic acid test result, thus highlighting the importance of CT imaging assessment [5].

Some typical radiological findings including subpleural ground-glass opacities (GGO) and consolidation have been reported as well as the dynamic evolution of these lesions [6–10]. However, these measurements were mainly based on visual evaluation, which are subjective and inaccurate. In addition, imaging evolution according to disease severity has rarely been reported, which we believe is critical for understanding the nature of the disease and monitoring disease change in a stratified manner.

In this retrospective study, quantitative assessment of imaging characteristics and dynamic evolution was evaluated. Comparison was made among patients with variable disease severity.

Materials and Methods

This study was approved by the ethics committee of Zhongda hospital (2020ZDSYLL013-P01 and 2020ZDSYLL019-P01) and informed consent was waived due to the emergent event of the pandemic.

Clinical information and imaging data for all COVID-19 patients diagnosed in Jiangsu before Feb 18, 2020 were obtained, retrospectively from electronic medical records, established by the Department of Health, Jiangsu province.

Patients with no clinical records or with missing, incomplete, or poor-quality chest CT images

1 were excluded. Figure 1 shows the detailed flow chart of this study.

2
3 Based on the 5th edition of the guideline for diagnosis and treatment of COVID-19, published by
4 National Health Commission of the People’s Republic of China on February 8, 2020, patients
5 were assigned into three groups, classified according to disease severity; asymptomatic/mild,
6 moderate, or severe/critically ill. Patients were classified as (i) “asymptomatic” if they had no
7 symptoms of disease, (ii) “mild” if they had mild clinical symptoms, but no imaging abnormality,
8 (iii) “moderate” if they had one or more symptoms (fever, cough, diarrhea, etc.) and imaging
9 showed manifestations of pneumonia or (iv) “severe” if they had one of the following conditions:
10 a) respiratory distress presenting with respiratory rate ≥ 30 beats/min, b) mean oxygen saturation
11 in resting state $\leq 93\%$, c) arterial blood oxygen partial pressure/oxygen concentration ≤ 300
12 mmHg. (v) Patients with either shock, respiratory failure requiring mechanical ventilation, or
13 combined organ failure requiring admission to an intensive care unit (ICU) were classified as
14 “critically ill”.
15

16
17 In order to analyze the evolution of imaging and clinical characteristics, the day when the initial
18 symptoms emerged was defined as day 1. When no initial symptoms were reported, the date of
19 outpatient visit was used as day 1. The time points for each CT scan, change of severity grading
20 relative to day 1 were recorded and were further assigned to day 1-3, day 4-6, day 7-9, day 10-12,
21 day 13-15 and beyond day 15.
22

23 CT acquisition

24
25 CT imaging was performed using multi-slicer CT scanners. Thin section images were collected
26 preferentially. For further details relating to the acquisition of CT images please see Table S1. All
27 raw data with format of Digital Imaging and Communications in Medicine were then transferred
28 to work stations for post-processing.
29

30 Imaging analysis

31
32 Lung segmentation, lesion extraction and labeling were performed using a dedicated artificial
33 intelligence (AI) system with deep learning algorithm for pulmonary pneumonia (Deepwise &
34 League of PhD Technology Co.Ltd). The AI algorithm achieved a dice of 0.97 in the HOUSE
35 dataset (easy) and 0.89 in the LOLA dataset (hard), which proved its robustness. The accuracy of
36

1 the AI system in lesion extraction and labeling was also manually checked by an investigator
2 (Y.W.) with more than 10 years of experience in chest imaging. Bilateral lungs were segmented
3 into right upper lobe, right middle lobe, right lower lobe, left upper lobe and left lower lobe
4 automatically, and extraction of pulmonary opacities was carried out at the same time. All
5 extracted opacity pieces were annotated as GGO or consolidation by the AI system and were
6 approved by an investigator (Y.W.). The masks of opacities and each lung's lobes were saved for
7 further voxel-based measurements including volume, X-ray attenuation and location. Detailed
8 information regarding segmentation and lesion extraction are available in supplemental methods.
9 Further assessment of segmented lobes and extracted opacities was performed as follows:

- 10 1) Volume measurement: included volume of bilateral lungs, GGO, consolidation, GGO +
11 consolidation, and aerated lung.
- 12 2) Density measurement: included the X-ray attenuation of bilateral lungs, overall opacities,
13 opacities in upper lobes including bilateral upper lobes and right middle lobe and opacities in
14 bilateral lower lobes.
- 15 3) Location analysis: A standard lung was selected from a healthy 37-year male without lung
16 abnormalities. Subsequent registration and projection of all included chest CT images to the
17 standard lung was performed. Voxel-based frequencies of opacity were measured by drawing
18 five volumes of interest (VOIs) in the standard lung, with each of the VOI larger than 15 mL.
19 Four VOIs were placed in the subpleural areas (within 15 mm from the pleura), which were
20 right posteroinferior subpleural area, right posterosuperior subpleural area, right anterior
21 subpleural area, right medial subpleural area, and the last one was placed in the right central
22 area 20 mm away from the pleura (Figure S1). The number of lobes with pulmonary opacities
23 was also recorded, and scored from 0 to 5, with 5 indicating all 5 lobes were involved.
- 24 4) Dynamic evolution: Dynamic change of volume, density, and frequency of opacities by
25 location from symptom onset (day 1) to beyond day 15 were investigated.

26 Clinical and laboratory characteristics

27 Demographic information, exposure type, initial symptoms (fever, cough, sputum, shortness of
28 breath, dyspnea, anorexia or diarrhea), possible exposure time, time of initial symptoms, date of
29 admission to hospital, comorbidity, and clinical laboratory findings including arterial oxygen

1 saturation (SaO₂), blood cell counts (blood leukocyte count, lymphocyte count, and platelet count)
2 and biomarkers of inflammation (C-reactive protein level, procalcitonin level, lactate
3 dehydrogenase), hepatic and renal function (aspartate aminotransferase level, alanine
4 aminotransferase level, creatinine level), and coagulation (D-dimer level) were collected.
5
6
7
8
9

10 Statistical analysis

11 All consecutive data were listed as means ± standard deviations (SDs) or medians with
12 interquartile ranges (IQRs) for Gaussian and skewed distributed data. Skewed distributed data
13 were tried to converted to Gaussian distribution by logarithmic transformation for variance
14 analysis. Chi-square test, Kruskal-Wallis or Mann-Whitney test were used to examine statistical
15 differences for ratio and skewed distributed data. All statistical analyses were performed using R
16 statistical software version 3.0.3.
17
18
19
20
21
22
23
24
25
26
27
28

29 Results

30 A total of 626 patients diagnosed with COVID-19 from 24 designated hospitals in Jiangsu
31 province were initially recruited to this study. One hundred and forty-two patients were excluded
32 from the study because of either no clinical records or missing or incomplete chest CT images, or
33 images with poor quality (Figure 1). The remaining 484 patients from 21 hospitals (3 were
34 excluded) were assigned to three severity groups (asymptomatic/mild, n=63; moderate, n=378;
35 severe/critically ill, n=43). Baseline characteristics were shown in Table 1. There was marked
36 disparity in median age between the three groups, manifesting as an increased age with increased
37 severity (p < .001). Fever (up to 83.7%) and cough/sputum (up to 69.8%) were the most common
38 symptoms in symptomatic patients. Analyses of laboratory test results for SaO₂, blood leukocyte
39 count, lymphocyte count, platelet count showed downward trends from asymptomatic/mild to
40 severe/critically ill. Conversely, C-reactive protein, lactate dehydrogenase, aspartate
41 aminotransferase and D-dimer concentrations above the normal range (≥ 10 mg/L, ≥ 250 U/L, $>$
42 40 U/L and ≥ 0.5 mg/L, respectively) tended to be more common in patients with severe disease.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 membrane oxygenation (34.9%, $p < .001$).

2 3 4 **Imaging characteristics by severity**

5
6 A total of 954 CT scans were performed in the 484 patients (asymptomatic/mild 122 [12.8%],
7 moderate 747 [78.3%], severe/critically ill 85 [8.9%]). Number of CT scans by disease severity
8 and time points were illustrated in Figure S2. The imaging characteristics are shown in Table 2.
9
10 Among the asymptomatic/mild group, 14.8% of CT scans showed no abnormal findings, and this
11 was significantly greater than for the other two groups ($p < .001$). When pooling CT scans at
12 different time points together, volume, density and location demonstrated significant differences
13 between the three groups. The severe/critically ill group showed the lowest total lung volume and
14 aerated lung and greatest volume of pulmonary opacities with 3548.7 mL, 2557.0 mL and 491.4
15 mL, respectively. For different components and locations of opacities, volume of consolidation
16 was more than GGO and volume of opacities in the lower lungs were more than that in the upper
17 lungs. Declines were found in attenuation as disease severity decreased.

18
19 Heterogenous distribution of the pulmonary opacities was observed in all groups. The most
20 common location for opacities was the subpleural area of posteroinferior lung (Figure S3), most
21 prominently in the severe/critically ill group with frequency of 45.3%, followed by the subpleural
22 area of posterosuperior lung (32.6%), the other areas (anterior and medial subpleural areas, central
23 area) were comparable with frequencies of 22.1% to 26.7%. The frequencies dropped with
24 decreased disease severity, in all locations of the lung (Table 2, Figure 2).

25
26 In patients in the severe/critically ill group, significantly more lung lobes were involved compared
27 to the other two groups, with median number of lobes of 5 (5 to 5), 5 (3 to 5) and 3 (1 to 4),
28 respectively, $P < .001$.

29 30 31 **Dynamic evolution of imaging characteristics**

32
33 The three groups showed different progressive and regressive imaging patterns (see supplemental
34 video).

35
36 The opacity volume was the greatest in the severe/critically ill group during the whole study
37 period (Figure 3A). Time series showed that opacity volumes (mainly for consolidation) continued
38 to increase in the severe/critically ill group, reaching 30.3% of the whole lung beyond day 15.

1 However, for the moderate group, opacity volume maintained a steady state after day 13-15,
2 account of 7.7% of the whole lung. In the asymptomatic/mild group, the highest opacity volume
3 was on day 1-3 (mean: 1.9%, 95% confidence intervals [CI]: 3.2%), which dropped gradually to
4 the lowest level beyond day 15 (mean: 0.9%, 95% CI: 0.3%) (Figure 3B). When classifying the
5 opacities into GGO and consolidation, a remarkable decrease trend of GGO was observed
6 compared to increase trend of consolidation in the severe/critically ill group.
7
8
9
10
11
12

13
14 In the moderate group, the attenuation showed a trend of increase in the initial 9 days after
15 symptom onset, and decrease after day 12. Overall median attenuation in the severe/critically ill
16 group was significantly higher than in the moderate group (-576 HU vs -634 HU, $p = 0.002$).
17
18

19 Opacities in the lower lobes had higher attenuation than that in the upper lobes (-534 HU vs -634
20 HU for the severe/critically ill group, -624 HU vs -676 HU for the moderate group, $p < .001$). An
21 increase trend of attenuation was perceived beyond day 15 in the severe/critically ill group,
22 compared to continuous decline in the moderate group (Figure 3C, Figure 4).
23
24
25
26
27
28

29 Change of opacity frequency by day synchronized with the volume, most evidently in the
30 posteroinferior subpleural area, reaching 61.6% in severe/critically ill group, versus 25.1% and
31 5.5% in the moderate and the asymptomatic/mild group, respectively (Figure 3D).
32
33
34
35
36
37

38 Discussion

39 In this province-based multicentre study, we have described CT imaging patterns and dynamic
40 evolution in patients with COVID-19, according to disease severity. Jiangsu, an eastern Chinese
41 province, with an area of 40,000 square miles and a population of about 80 million (ranked fifth in
42 China provinces) is a representative district, and our findings may be of relevance to many other
43 countries. The low death toll (no deaths in this study) and high proportion of patients with
44 moderate disease severity due to COVID-19 observed in our study are similar to reports from
45 many other countries [2], and may indicate the common nature of COVID-19.
46
47
48
49
50
51
52
53
54
55

56 The demographics and clinical/laboratory findings in our study are also comparable to previously
57 reported data [3, 8, 11]. Severe cases tended to be older, had a shorter incubation period, had more
58 comorbidities, abnormal blood cell counts, abnormal inflammatory biomarkers, liver dysfunction
59
60
61
62
63
64
65

1 and experienced more serious adverse events. The early CT findings (3 days after onset) in this
2 study were characterized as predominately subpleural GGO and posterior basal predominance for
3 patients with different disease severity, consistent with previous studies [6, 12].
4
5
6

7
8 There was a tendency of subpleural distribution for pulmonary opacities, consistent with the
9 underlying pathogenic pattern that distal bronchioles as well as alveolar epithelial cells impaired
10 in viral pneumonia [13, 14]. The posterior basal predominance shown in the heat map may due to
11 the predilection of atelectasis posteriorly, corresponding to heterogeneous pulmonary opacity
12 distribution in patients with acute respiratory distress syndrome [15]. Among all subpleural areas,
13 the posteroinferior area of the lung showed leading frequency of opacity distribution as indicated
14 in Figure 3D, which may due to the anatomical characteristics of the bronchus: more vertical for
15 lower lobes compared with the other lobes. This makes the lower lobes more susceptible to
16 pathogen attack [8]. Our study further demonstrated a discrepancy in subpleural distribution which
17 has not been elaborated in previous studies: the medial and anterior subpleural areas were less
18 frequently involved compared to the posterior subpleural areas.
19
20
21
22
23
24
25
26
27
28
29
30
31

32
33 Part of the pulmonary opacities presented as GGO in this study, especially in the early stages of
34 disease. This finding is consistent with several studies [8, 10, 16–18]. Although our understanding
35 of the pathological mechanisms and effects of this specific novel coronavirus are limited, there is
36 some evidence to explain the underlying causes of these radiological manifestations. In a study of
37 two patients with lung adenocarcinoma surgery superimposed with COVID-19, damage of alveoli
38 together with proteinaceous and fibrous exudation, accounted for the early appearance of GGO on
39 chest CT [19]. In studies of severe acute respiratory syndrome (SARS), focal lung injury was
40 related to early radiologic findings [20]. As SARS and COVID-19 are both caused by coronavirus,
41 it is possible that some of their pathological process overlap [21]. As the disease progresses, more
42 inflammatory cells infiltrate the alveoli and interstitial space, followed by diffuse alveolar damage
43 and hyaline membrane formation [22], which result in an appearance of consolidation on CT
44 examination.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 As for the dynamic evolution, a study of 63 COVID-19 patients from Wuhan showed an increased
2 range of GGO and consolidation in 3-14 days after onset of symptoms [17]. Pan et al. identified a
3 peak stage of 9-13 days for lung involvement after symptom onset in 21 patients [10], compared
4 to 6-11 days from another study of 90 patients [9]. In our study, we used an AI algorithm to
5 automatically and quantitatively measure the percentage of opacity volume in 484 patients, which
6 is different from scoring system based on visual evaluation in previous studies [9, 10, 17]. We
7 concluded a peak stage of 13-15 days for opacity volume after symptom onset in moderately ill
8 patients – the large majority in this study. Notably, for severe/critically ill patients, this peak stage
9 extended to beyond 15 days, while for mild/asymptomatic patients, the peak stage was just at the
10 first 3 day after symptom onset. In severe/critically ill patients, different evolution patterns for
11 GGO and consolidation were observed. There was a trend that GGO reduced continuously along
12 with consolidation aggregation, suggesting a transformation of GGO to consolidation, during the
13 course of disease. Varied patterns of imaging evolution are particularly useful in dynamically
14 evaluating disease severity.

15 AI has been developed fast in recent years, and has already been used to distinguish pneumonia in
16 COVID-19 from community acquired pneumonia [23]. The preliminary results are promising, but
17 it should be noted the pre-test probability of COVID-19 varied with cities as well as countries, the
18 positive predictive value of CT, even combined with AI, may low in areas with low pre-test
19 probability [24]. It should be avoided to overstate the role of AI in the diagnosis of COVID-19. In
20 this study, however, we did not use AI to diagnose COVID-19, but for pulmonary lobe
21 segmentation, lesion extraction and GGO / consolidation labeling, these techniques are relatively
22 mature. And the accuracy was verified in the study.

23 Our retrospective study has several limitations. Firstly, prospective studies of CT examination and
24 patterns of evolution should be undertaken and validated in more institutions. Secondly, the
25 relatively small sample size of mild/asymptomatic cases resulted in relatively large variation in
26 certain measurements. Consequently, although trends for some changes were observed, they did
27 not reach statistical significance. Therefore, further studies that include more patients with
28 asymptomatic/mild disease cases are required to strengthen the statistical power. Thirdly, opacity
29 changes on CT were still progressing in the severe/critically ill patient group at the end of the
30 study period (beyond day 15), Therefore further studies are required to prolong the follow-up

1 period to determine the potential break point for these patients. Finally, since CT findings were
2 significantly different between the severity groups, we hypothesize that a combined CT score
3 could be developed to classify disease severity, and predict disease outcome at an early stage. We
4 plan to undertake this work in the near future.
5
6
7
8
9

10 Conclusion

11 In this multicentre study of patients with COVID-19, we have shown that pulmonary opacities
12 vary in volume, density and location, as well as the dynamic evolution, according to disease
13 severity. Our findings provide insight into the nature of the disease and are potentially valuable in
14 the evaluation and monitoring of the disease.
15
16
17
18
19
20
21
22
23
24
25
26
27

28 ***Funding information:***

29 This study has received funding by the Ministry of Science and Technology of the
30 People's Republic of China (2020YFC084370067)
31
32
33
34
35
36
37

38 ***Compliance with Ethical Standards***

39 ***Guarantor:***

40 The scientific guarantor of this publication is Shenghong Ju.
41
42
43
44
45
46
47

48 ***Conflict of Interest:***

49 The authors of this manuscript declare no relationships with any companies whose
50 products or services may be related to the subject matter of the article.
51
52
53
54
55
56

57 ***Statistics and Biometry:***

58 No complex statistical methods were necessary for this paper.
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Informed Consent:

Written informed consent was waived by the Institutional Review Board.

Ethical Approval:

Institutional Review Board approval was obtained.

Methodology

- retrospective
- observational
- multicenter study

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Zu ZY, Jiang MD, Xu PP et al (2020) Coronavirus Disease 2019 (COVID-19): A Perspective from China. *Radiology*. DOI: 10.1148/radiol.2020200490
2. World Health Organization (2020) Coronavirus disease 2019 (COVID-19) Situation Report – 65. World Health Organization. Available via <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
3. Guan W, Ni Z, Hu Y et al (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* Feb 28:NEJMoa2002032
4. Jiangsu commission of health Comfirmed cases of 2019 novel coronavirus. http://wjw.jiangsu.gov.cn/art/2020/2/19/art_7290_8976979.html.
5. National Health Commission of the People’s Republic of China Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 5). February 8, 2020. Available via <http://www.nhc.gov.cn/xcs/zhengcwj/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml>
6. Shi H, Han X, Zheng C (2020) Evolution of CT Manifestations in a Patient Recovered from 2019 Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China. *Radiology*. DOI: 10.1148/radiol.2020200269
7. Kanne JP (2020) Chest CT Findings in 2019 Novel Coronavirus (2019-nCoV) Infections from Wuhan, China: Key Points for the Radiologist. *Radiology* DOI: 10.1148/radiol.2020200241
8. Shi H, Han X, Jiang N et al (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 20:425–434
9. Wang Y, Dong C, Hu Y et al (2020) Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology*. DOI: 10.1148/radiol.2020200843
10. Pan F, Ye T, Sun P et al (2020) Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology*. DOI: 10.1148/radiol.2020200370
11. Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395:497–506
12. Lei J, Li J, Li X, Qi X (2020) CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia. *Radiology*. DOI: 10.1148/radiol.2020200236

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
13. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR (2011) Viral pneumonia. *Lancet* 377:1264–1275
14. Kim EA, Lee KS, Primack SL et al (2002) Viral pneumonias in adults: radiologic and pathologic findings. *Radiographics* 22 Spec No:S137-49
15. Mbbs SS, Rao P, Frcr M et al (2012) Imaging of Acute Respiratory Distress Syndrome. *Respir Care* 57:607-612
16. Peikai Huang, Tianzhu Liu LH (2020) Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion. *Radiology*. DOI: 10.1148/radiol.2020200330
17. Pan Y, Guan H, Zhou S et al (2020) Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. *Eur Radiol*. DOI: 10.1007/s00330-020-06731-x
18. Xie X, Zhong Z, Zhao W et al (2020) Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. *Radiology*. DOI: 10.1148/radiol.2020200343
19. Tian S, Hu W, Niu L et al (2020) Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. *J Thorac Oncol* Feb 27:pii: S1556-0864(20)30132-5
20. Paul NS, Roberts H, Butany J et al (2004) Radiologic pattern of disease in patients with severe acute respiratory syndrome: The Toronto experience. *Radiographics* 24:553–563
21. Liu J, Zheng X, Tong Q et al (2020) Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS- CoV, MERS- CoV, and 2019- nCoV. *J Med Virol* 92:491–494
22. Xu Z, Shi L, Wang Y et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2600:19–21
23. Li L, Qin L, Xu Z et al (2020) Artificial Intelligence Distinguishes COVID-19 from Community Acquired Pneumonia on Chest CT. *Radiology*. DOI: 10.1148/radiol.2020200905
24. Hope MD, Raptis CA, Shah A et al (2020) A role for CT in COVID-19? What data really tell us so far. *Lancet* 395:1189–1190

1 **Legends**

2 Table 1 Baseline characteristics of study patients.

3
4
5 Table 2. Computed tomography (CT) results in patients with COVID-19, according to disease
6 severity

7
8
9 Figure 1. Flowchart of the study

10
11 Figure 2. Three-dimensional heat maps show the frequency of location of pulmonary opacities in
12 COVID-19 from the onset of symptoms (day 1) to beyond day 15. Asymptomatic/mild patients
13 have trace opacities, resolving partially after 15 days (top row). Moderately ill patients have more
14 opacities and peaked on day 13-15, predominantly located in the posteroinferior subpleural area
15 (middle row). Severe/critically ill patients have the most prominent opacities and continue to
16 progress beyond day 15 (bottom row). Axial frequency map shows typical pattern of posterior
17 subpleural distribution of the opacities with decreased frequency in the anterior and medial
18 subpleural areas.
19
20
21
22
23
24
25
26

27
28
29 Figure 3. CT measurements changing by day (A-D). (A) In the severe/critically ill group, volume
30 of aerated lung decreased while pulmonary opacities increased by day. (B) Volume of
31 consolidation kept growing beyond 15 days in the severe/critically ill group, while peaked on day
32 13-15 in the moderate group. (C) The density of opacities dropped after day 12 in the moderate
33 group; opacities in lower lobes had higher attenuation than that in upper lobes. (D) Posteroinferior
34 subpleural area was the most common involved location in the lung, and the variation trend was
35 similar to volume change in figure B.
36
37
38
39
40
41
42
43
44

45
46 Figure 4. A 64-year old male diagnosed with moderate COVID-19. Non-contrast chest CT were
47 performed on day 5, 8, 10, 15 after the onset of initial symptoms (A-D). The pulmonary opacities
48 kept similar volume while the density decreased heterogeneously on day 15 compared to day 10.
49
50
51
52

53
54 Figure 5. A 56-year old female diagnosed with severe COVID-19. Non-contrast chest CT were
55 performed on day 5, 11, 14, 17 after the onset of initial symptoms (A-D). The bilateral subpleural
56 opacities progressed to consolidation on day 17.
57
58
59
60
61
62
63
64
65

Table 1 Baseline characteristics of study patients.

Characteristics	Disease severity			
	Asymptomatic/mild (n= 63, 13.0%)	Moderate (n= 378, 78.1%)	Sever/critically ill (n= 43, 8.9%)	p value
Age, years	33 (22, 51)	46 (34, 56)	59 (52, 71)	<.001
Gender, male	31/63 (49.2%)	202/378 (53.4%)	27/43 (62.8%)	0.377
Incubation period, days	8 (5, 11)	6 (3, 10)	5 (3, 8)	0.125
Initial symptoms				
Fever	14/30 (46.7%) ^c	278/378 (73.5%)	36/43 (83.7%)	<.001
Cough/sputum	19/30 (63.3%) ^c	224/378 (59.3%)	30/43 (69.8%)	<.001
Shortness of breath/Dyspnea	0/30 (0%) ^c	10/378 (2.7%)	5/43 (11.6%)	0.007
Comorbidity^a	8/63 (12.7%)	76/378 (20.1%)	16/43 (37.2%)	0.008
Exposure type				
Wuhan exposure	18/63 (28.6%)	148/378 (39.2%)	16/43 (37.2%)	0.275
COVID-19 patients exposure	34/63 (54.0%)	139/378 (36.8%)	12/43 (27.9%)	0.012
Contact history ^b	8/63 (12.7%)	40/378 (10.6%)	8/43 (18.6%)	0.284
No exposure	3/63 (4.8%)	51/378 (13.5%)	7/43 (16.3%)	0.116
Type of disease				
Single onset	10/63 (15.9%)	199/378 (52.6%)	23/43 (53.5%)	<.001
Clustering onset	53/63 (84.1%)	179/378 (47.4%)	20/43 (46.5%)	<.001
Laboratory tests				
SaO ₂ , %	98.2 (98.0, 98.4)	97.9 (96.4, 99.0)	95.3 (93.2, 97.3)	<.001
Blood leukocyte count, *10 ⁹ /L	5.3 (4.5, 6.6)	4.8 (3.8, 6.0)	4.2 (3.5, 5.9)	0.033
<4*10 ⁹ /L	9/57 (15.8%)	93/309 (30.1%)	14/37 (37.8%)	0.040
>10*10 ⁹ /L	1/57 (1.8%)	5/309 (1.6%)	3/37 (8.1%)	0.077
Lymphocyte count, *10 ⁹ /L	1.8 (1.3, 2.5)	1.3 (1.0, 1.7)	0.6 (0.5, 0.9)	<.001
<1.5*10 ⁹ /L	18/54 (33.3%)	195/318 (61.3%)	36/37 (97.3%)	<.001
Platelet count, *10 ⁹ /L	216 (164, 263)	182 (152, 212)	154 (120, 191)	<.001
<150*10 ⁹ /L	9/58 (15.5%)	71/322 (22.0%)	15/37 (40.5%)	0.014

C-reactive protein, $\geq 10\text{mg/L}$	4/50 (8.0%)	143/300 (47.7%)	19/31 (61.3%)	<.001
------------------------------------------	-------------	-----------------	---------------	-------

Table 2. Computed tomography (CT) results in patients with COVID-19, according to disease severity

Procalcitonin, $\geq 0.5\text{ng/mL}$	5/50 (10.0%)	55/295 (18.6%)	6/27 (22.2%)	0.274
Lactate dehydrogenase, $\geq 250\text{U/L}$	6/37 (16.2%)	103/232 (44.4%)	17/26 (65.4%)	<.001
Aspartate aminotransferase, $>40\text{ U/L}$	4/48 (8.3%)	71/270 (26.3%)	13/30 (43.3%)	0.002
Alanine aminotransferase, $>40\text{U/L}$	6/46 (13%)	70/273 (25.6%)	8/30 (26.7%)	0.170
D-dimer, $\geq 0.5\text{mg/L}$	11/54 (20.4%)	75/311 (24.1%)	17/36 (47.2%)	0.007
Creatine, $\mu\text{mol/L}$	63 (47, 79)	63 (50, 78)	62 (51, 82)	0.975
ICU /IMV/CRRT/ECMO	1/63 (1.6%)	13/378 (3.4%)	15/43 (34.9%)	<.001

Categorical variables are expressed as number (percentage) while continuous variables are described as median and interquartile range.

a: Comorbidity include hypertension, coronary heart disease, cardiac dysfunction III-IV, poor physical fitness (unable to climb stairs, do daily housework, etc.), gastrointestinal hemorrhage caused by cirrhosis, hepatic encephalopathy and portal hypertension, diabetes, chronic kidney dysfunction, dialysis, malignant tumor, hematological malignancies, connective tissue disease, stroke.

b: Contact history refers to those patients who had contact with people from Wuhan before the onset of disease.

c: A total of 33 patients were asymptomatic in the asymptomatic/mild group and were excluded when calculating the symptom percentage.

ICU: intensive care unit, IMV: Invasive Mechanical Ventilation, CRRT: Continuous Renal Replacement Therapy, ECMO: Extracorporeal Membrane Oxygenation.

Characteristics	Disease severity			
	Asymptomatic/mild (n =63, 13.0%)	Moderate (n= 378, 78.1%)	Severe/critically ill (n= 43, 8.9%)	P value
Number of chest CT examinations	122/954 (12.8%)	747/954 (78.3%)	85/954 (8.9%)	-
Number of CT examinations without pulmonary opacity	18/122 (14.8%)	15/747 (2.0%)	0/85 (0%)	<.001
Number of CT examinations with slice thickness ≤ 3 mm	114/122 (93.4%)	654/747 (87.6%)	72/85 (84.7%)	0.108
Volume (mL)				
Whole lung	4637.4 (3687.7, 5724.5)	4429.7 (3575.9, 5338.5)	3548.7 (2538.3, 4393.6)	<.001
Aerated lung	4636.0 (3585.6, 5647.4)	4216.6 (3307.1, 5094.7)	2557.0 (1921.0, 3921.7)	<.001
Pulmonary opacities	1.7 (0.1, 44.9)	129.8 (34.0, 302.5)	491.4 (199.0, 1041.0)	<.001
Ground glass opacities	0.1 (0, 5.7)	9.1 (1.2, 32.5)	14.8 (0.9, 66.4)	<.001
Consolidation	0.4 (0, 20.3)	97.5 (16.8, 238.8)	437.3 (134.2, 977.8)	<.001
Opacities in the upper lobes	0 (0, 1.8)	22 (0.7, 98.7)	227.7 (46.6, 496.2)	<.001
Opacities in the lower lobes	0 (0, 28.7)	76.2 (13.8, 190.1)	288.3 (102.4, 554.6)	<.001
Density (X-ray attenuation, Hu)				
Whole lung	-847 (-864, -821)	-826 (-856, -786)	-750 (-802, -684)	<.001
Pulmonary opacities	-602.5 (-713, -484)	-634 (-711, -540)	-576 (-666, -523)	0.003
Opacities in the upper lobes	-656 (-736, -566)	-676 (-744, -577)	-634 (-696, -560)	0.009
Opacities in the lower lobes	-586 (-689, -479)	-624 (-708, -518)	-534 (-645, -443)	<.001
Frequencies of opacity by location (%)				
Right posteroinferior subpleural area	4.7 (2.4, 7.1)	20.5 (18.6, 22.6)	45.3 (43.0, 48.8)	<.001
Right posterosuperior subpleural area	1.6 (0.8, 1.6)	10.8 (8.5, 12.6)	32.6 (29.1, 34.9)	<.001
Right anterior subpleural area	1.6 (1.6, 3.1)	5.3 (4.4, 6.6)	24.4 (20.9, 26.7)	<.001
Right medial subpleural area	1.6 (1.6, 1.6)	4.1 (3.5, 5.2)	22.1 (19.8, 26.7)	<.001
Right central area	1.6 (0.8, 1.6)	4.9 (4.5, 5.5)	26.7 (23.3, 27.9)	<.001
Lung lobes involved	3 (1, 4)	5 (3, 5)	5 (5, 5)	<.001

Variables are described as number (percentage) or median and interquartile range.

Upper lobes include left upper lobe, right upper lobe and right middle lobe; Lower lobes include left lower lobe and right lower lobe.




Figure 2

[Click here to access/download;Figure;Fig 2 Evolution of opacity distribution and quantity 3d.tif](#)







Figure 3

[Click here to access/download;Figure;Fig 3.tif](#)





Funding information:

This study has received funding by the Ministry of Science and Technology of the People's Republic of China (2020YFC084370067)

Compliance with Ethical Standards***Guarantor:***

The scientific guarantor of this publication is Shenghong Ju.

Conflict of Interest:

The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and Biometry:

No complex statistical methods were necessary for this paper.

Informed Consent:

Written informed consent was waived by the Institutional Review Board.

Ethical Approval:

Institutional Review Board approval was obtained.

Methodology


- retrospective
- observational
- multicenter study

video of CT evolution



Click here to access/download
Supplementary Material
CT evolution.mp4





[Click here to access/download](#)

Supplementary Material

EURAD-20-01283_supplementary materials.docx



